01-Jun-2005 - QIAGEN GmbH

QIAGEN Acquires artus GmbH

QIAGEN N.V. announced that its wholly owned subsidiary QIAGEN GmbH has entered into a definitive agreement to acquire artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH, an established leader in PCR-based molecular diagnostic tests for pathogenenic, genotyping and pharmacogenomic testing. QIAGEN expects that this transaction will add approximately US$15 million in net sales and US$1.5 - 2.0 million in net income to QIAGEN's 2006 financial results.

QIAGEN believes that this acquisition is a perfect fit in its strategy to increase QIAGEN's value as a partner to the molecular diagnostics industry. In addition to its leading position in preanalytical sample preparation in molecular diagnostics, QIAGEN is now able to offer optimized and synchronized combinations of preanalytical sample preparation and diagnostic assay solutions to its partners in molecular diagnostics. By providing the opportunity for partners in molecular diagnostics to expand their portfolio by adding artus' validated assays, QIAGEN intends to further contribute to accelerating the growth of molecular diagnostics by broadening the menu of tests available on today's diagnostic platforms.

Subject to the terms of the acquisition agreement, QIAGEN will pay approximately US$39.2 million in cash in exchange for all of the outstanding capital stock of artus GmbH. Approximately US$11.6 million of this consideration will be paid into escrow and will be released subject to certain milestones being met. QIAGEN expects to incur charges relating to the acquisition of approximately US$2.0 - 3.0 million in its financial results for the second quarter of 2005.

Facts, background information, dossiers
More about Qiagen
  • News

    QIAGEN fully acquires NeuMoDx Molecular

    QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed ... more

    Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement

    Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN. The amendment provides for an increase from the original of ... more

    QIAGEN names Thierry Bernard as Chief Executive Officer

    QIAGEN announced that Thierry Bernard has been named Chief Executive Officer. Additionally, a Joint Meeting of the Supervisory Board and the Managing Board has resolved to propose Mr. Bernard, who has been with QIAGEN since 2015, for election as Chief Executive Officer and a Managing Direct ... more

  • Companies

    QIAGEN GmbH

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN Instruments AG

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN N.V.

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

More about artus